Minerva Neurosciences, Inc. (NERV) Stock Profile — Insider Trades & Financials

Net Income-$283.7M

EPS$-1.29

Market Cap$234.5M

Price Performance

Historical data including institutional events

Loading price data...

Company Profile

Remy Luthringer

CEO & Executive Director

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.

Founded: 2007
Employees: 8
Headquarters: Burlington, Massachusetts, United States
Website

⚡

Core Efficiency

ROE?

201.54%

ROA?

-289.55%

D/E Ratio?

-1.66

📊

Profitability Ratios

Current Ratio?

36.28

Loading comparison...

Earnings Calendar

Filing history and next expected filing date

Next Expected Filing

Aug 5, 2026 (in 118 days)

Annual Report (10-K) — Based on filing pattern

Aug 5, 2026

Predicted10-K

Mar 11, 2026

10-KQ4 20255d after period end

Nov 5, 2025

10-QQ3 20255d after period end

Aug 14, 2025

10-QQ2 20256d after period end

May 13, 2025

10-QQ1 20255d after period end

Apr 29, 2025

10-K/AQ4 202411d after period end

Nov 5, 2024

10-QQ3 20245d after period end

Aug 6, 2024

10-QQ2 20245d after period end

May 1, 2024

10-QQ1 20245d after period end

Loading company sections...

Minerva Neurosciences, Inc.

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Earnings Calendar

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness